Weight loss with once-weekly dulaglutide versus insulin glargine, both with insulin lispro (+/- metformin), in patients with type 2 diabetes (T2D) from AWARD-4, stratified by base…

Objective: For T2D patients with increased BMI ≥27 kg/m2 or > 35 kg/m2, German national guidelines recommend weight loss of ˜5% or > 10%, respectively. Bodyweight data from the open-label AWARD-4 trial comparing once-weekly dulaglutide 1.5 mg vs. glargine, both with lispro ± metformin, were analysed post hoc by baseline BMI category. Methods: Proportions of patients were described and compared for dulaglutide 1.5 mg (N = 295) vs. glargine (N = 296) across baseline BMI categories (≥27-< 35/≥35 kg/m2) for weight loss ≥3%, ≥5% or ≥10% and the composite endpoint (HbA1c < 7% and weight loss ≥3%) after 52 weeks. Resul…